By Counterforce Health Team in Rezlidhia (olutasidenib) —

How to Get Rezlidhia (Olutasidenib) Covered by Cigna in Washington: Prior Authorization Forms, Appeals Process & Success Strategies

Answer Box: Getting Started Today

Cigna requires prior authorization for Rezlidhia (olutasidenib) in Washington for adults ≥18 with relapsed/refractory AML and confirmed IDH1 mutation via FDA-approved testing. Submit through ExpressPAth or CoverMyMeds with mutation results, diagnosis documentation, and treatment history. If denied, you have 180 days to appeal internally, then request external review through Washington's Independent Review Organization (IRO) process. Start today: Contact your oncologist to confirm IDH1 test results and gather prior therapy records for the PA submission.

Table of Contents

  1. Plan Types & Coverage Implications
  2. Formulary Status & Tier Placement
  3. Prior Authorization Requirements
  4. Specialty Pharmacy Process
  5. Cost-Share Basics
  6. Submission Process
  7. Common Approval Patterns
  8. Appeals Process in Washington
  9. FAQ
  10. Sources & Further Reading

Plan Types & Coverage Implications

Cigna offers HMO, PPO, and EPO plans in Washington, each with different network requirements that affect your access to oncology specialists and IDH1 testing:

Plan Type Oncology Specialist Access IDH1 Testing Coverage Referral Requirements
HMO In-network only (except emergencies) Covered if in-network and medically necessary PCP referral typically required
PPO In/out-of-network (higher cost out-of-network) Covered in/out-of-network No referrals needed
EPO In-network only (except emergencies) In-network coverage only Usually no referrals
Note: Self-funded employer plans may have different appeal rights than fully insured plans. Check your Summary Plan Description or call the member services number on your card to confirm.

Formulary Status & Tier Placement

Rezlidhia appears on Cigna's 2026 National Preferred Formulary with prior authorization requirements. The drug is managed through Express Scripts/Accredo for specialty medications and requires coverage criteria to be met before approval.

Alternative IDH1/AML Treatments on Cigna Formulary:

  • Ivosidenib (Tibsovo) - IDH1 inhibitor
  • Enasidenib (Idhifa) - IDH2 inhibitor
  • Gilteritinib (Xospata) - FLT3 inhibitor
  • Venetoclax-based regimens
  • Hypomethylating agents (HMA)

Prior Authorization Requirements

Cigna's CNF781 policy requires all of the following criteria:

Coverage Requirements Table

Requirement Documentation Needed Source
Age ≥18 years Date of birth verification Patient chart
Relapsed/refractory AML diagnosis Pathology report, bone marrow biopsy Clinical notes with ICD-10 codes
IDH1 mutation confirmation FDA-approved test results (PCR or NGS) CLIA-certified lab report
Board-certified prescriber Oncologist or hematologist credentials Provider verification
Monitoring plan Differentiation syndrome and hepatic toxicity protocols Treatment plan documentation
Tip: The most common denial reason is missing or incomplete IDH1 mutation documentation. Ensure your test was performed by an FDA-approved method and clearly shows the specific mutation subtype.

Specialty Pharmacy Process

Rezlidhia is typically dispensed through Cigna's specialty pharmacy partners:

  1. Express Scripts/Accredo: Primary specialty pharmacy network
  2. Patient enrollment: After PA approval, you'll be contacted to set up delivery
  3. Monitoring requirements: Regular lab work and clinical assessments per Cigna policy
  4. Refill coordination: Automatic with prescriber authorization

Contact Accredo patient services at the number on your approval letter for setup and delivery questions.

Cost-Share Basics

Specialty medications like Rezlidhia typically fall under your plan's highest cost-sharing tier. Your exact costs depend on:

  • Deductible status: Whether you've met your annual deductible
  • Coinsurance percentage: Often 20-40% for specialty drugs
  • Out-of-pocket maximum: Annual limit on your total costs

Potential Cost Support:

Submission Process

Step-by-Step: Fastest Path to Approval

  1. Confirm IDH1 mutation (Oncologist): Verify FDA-approved test results are available
  2. Gather documentation (Clinic staff): Collect diagnosis, prior therapies, treatment plan
  3. Submit PA (Prescriber): Use ExpressPAth or CoverMyMeds portal
  4. Track status (Patient/clinic): Monitor through Express Scripts member portal
  5. Respond to requests (Within 24-48 hours): Provide additional information if requested
  6. Receive decision (72 hours standard): Approval or denial notification
  7. Set up specialty pharmacy (If approved): Enroll with Accredo for delivery

Required Documentation Checklist

  • ✓ Current insurance card and member ID
  • ✓ Complete diagnosis with ICD-10 codes
  • ✓ IDH1 mutation test results (FDA-approved method)
  • ✓ Prior therapy history with dates and outcomes
  • ✓ Current treatment plan with monitoring protocols
  • ✓ Prescriber DEA and NPI numbers

Common Approval Patterns

Successful Rezlidhia submissions typically include:

Medical Necessity Letter Components:

  • Patient demographics and AML diagnosis timeline
  • Specific IDH1 mutation subtype (e.g., R132H, R132C)
  • Detailed prior treatment failures or contraindications
  • NCCN guideline citations (Category 2A recommendation)
  • Monitoring plan for differentiation syndrome
  • Expected treatment duration and goals
From our advocates: We've seen the strongest approvals when oncologists include a clear timeline of the patient's AML journey, specific mutation details from an FDA-approved test, and a detailed monitoring plan. Vague statements about "standard treatment failure" often lead to denials that require appeals.

When Counterforce Health reviews Rezlidhia cases, we focus on ensuring the IDH1 mutation documentation meets Cigna's exact specifications and that prior therapy documentation clearly establishes medical necessity. Our platform helps identify the specific evidence requirements and formats them according to Cigna's policy expectations.

Appeals Process in Washington

Internal Appeal (Required First Step)

  • Deadline: 180 calendar days from denial notice
  • Submission: Written appeal to Cigna Appeals Unit, PO Box 188011, Chattanooga, TN 37422
  • Timeline: Up to 60 days for standard review; expedited available if health jeopardized
  • Success rate: Approximately 25-35% when complete medical evidence submitted

Washington External Review (IRO Process)

After internal appeal denial, Washington residents can request external review:

  • Eligibility: Automatic for fully insured plans (verify with Washington Insurance Commissioner)
  • Deadline: 30 days from final internal denial
  • Process: Submit request to OIC or follow Cigna's instructions in denial letter
  • Timeline: 30 days standard; 72 hours expedited for urgent cases
  • Decision: Binding on Cigna if overturned

Washington OIC Consumer Advocacy: 1-800-562-6900 for assistance with appeals process.

Required Appeal Documents

  • Original denial letter and EOB
  • Updated clinical notes since denial
  • Additional supporting studies or guidelines
  • Peer review or second opinion letters
  • Patient impact statement

For complex cases involving rare diseases like AML with IDH1 mutations, Counterforce Health's platform can help structure appeals with the specific evidence and formatting that meets both Cigna's policy requirements and Washington's external review standards.

FAQ

Q: How long does Cigna prior authorization take for Rezlidhia in Washington? A: Standard PA decisions come within 72 hours; complex cases may take up to 15 business days. Expedited reviews (24 hours) are available for urgent medical situations.

Q: What if Rezlidhia is non-formulary on my plan? A: You can request a formulary exception with clinical justification. Include comparative efficacy data versus formulary alternatives and medical necessity documentation.

Q: Can I request an expedited appeal if my AML is progressing? A: Yes. Contact Cigna customer service at 1-800-882-4462 to request expedited review based on health jeopardy. Provide supporting clinical documentation.

Q: Does step therapy apply if I've failed treatments outside Washington? A: Prior therapy failures from any location count toward medical necessity. Ensure complete documentation of all prior treatments with dates and outcomes.

Q: What counts as an FDA-approved IDH1 test for Cigna? A: Tests like Abbott RealTime IDH1 CDx performed by CLIA-certified labs. Non-FDA approved tests typically result in denial.

Q: Can my oncologist do a peer-to-peer review if denied? A: Yes. Request peer-to-peer review through Cigna's provider services. This often resolves denials when clinical rationale can be discussed directly.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies and appeal procedures may vary by specific plan. Always consult your healthcare provider for medical decisions and verify current policy details with Cigna member services. For assistance with complex appeals, consider consulting with healthcare coverage advocates or legal professionals familiar with Washington insurance law.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.